HIF1A and acute myeloid leukemia: Administration of TH-302 after chemotherapy to mice with residual disease prolonged their survival (73), suggesting that specifically targeting of HIF-1α in the hypoxic niche may be a successful therapeutic strategy to specifically eliminate chemotherapy resistant AML (stem) cells.